Vertex Pharmaceuticals Inc
VRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000875320
In the last 90 days, Vertex Pharmaceuticals Inc insiders filed 0 open-market purchases and 3 sales; 1,763 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vertex Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $2.00M in total
- Insiders trading
- 3
- Net value
- −$2.00M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vertex Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| van Grunsven Jasper | EVP, CP and NPPO | 8,682 | Sep 10, 2026 | 1 |
| Ambrose Kristen | SVP & Chief Accounting Officer | 11,624 | Sep 1, 2026 | 7 |
| Sachs Bruce I | Director | 39,000 | Aug 31, 2026 | 6 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 53,572 | Jul 23, 2026 | 9 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 66,512 | Jul 23, 2026 | 7 |
| Garber Alan M | Director | 7,344 | Jul 17, 2026 | 3 |
| McKechnie Duncan | EVP, Chief Commercial Officer | 11,001 | Jul 7, 2026 | 8 |
| Liu Joy | EVP and Chief Legal Officer | 19,131 | Jul 6, 2026 | 5 |
| Bozic Carmen | EVP and CMO | 15,337 | Jun 30, 2026 | 15 |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 7,284 | May 19, 2026 | 5 |
| Carney Lloyd | Director | 6,315 | May 5, 2026 | 2 |
| Lagarde Michel | Director | 1,132 | May 5, 2026 | 1 |
| Upadhyay Suketu | Director | 1,558 | May 5, 2026 | 4 |
| Bhatia Sangeeta N. | Director | 4,924 | May 5, 2026 | 2 |
| McKenzie Diana | Director | 2,378 | May 5, 2026 | 1 |
| Schneider Jennifer | Director | 1,394 | May 5, 2026 | 1 |
| Thornberry Nancy | Director | 2,109 | May 5, 2026 | 1 |
| Kewalramani Reshma | CEO & President | 98,278 | Mar 3, 2026 | 6 |
| Wagner Charles F Jr | EVP, CO & FO | 47,042 | Feb 26, 2026 | 7 |
| Leiden Jeffrey M | Executive Chairman | 34,797 | Feb 26, 2026 | 5 |
| Biller Jonathan | EVP and Chief Legal Officer | 13,659 | Feb 26, 2026 | 7 |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 18,432 | Feb 26, 2026 | 6 |
| Altshuler David | EVP, Chief Scientific Officer | 34,477 | Jan 26, 2026 | 1 |
| Arbuckle Stuart A | EVP, COO | 63,368 | Jul 2, 2025 | 0 |
| Kearney Terrence C | Director | 6,536 | May 3, 2024 | 0 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | 32,038 | May 9, 2023 | 0 |
| McGlynn Margaret G | Director | 178 | May 3, 2023 | 0 |
| Lee Yuchun | Director | 1,875 | May 3, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 (view filing) | May 4 | 1 day | Bhatia Sangeeta N.Director | SSale | −318 | $423.73 | −$134.7K | −6.1%4.92K after | 10b5-1 |
| May 5, 2026 (view filing) | May 1 | 4 days | Liu JoyEVP and Chief Legal Officer | SSale | −1.10K | $425.02 | −$469.2K | −5.1%20.7K after | 10b5-1 |
| May 14, 2026 (view filing) | May 12 | 2 days | Bozic CarmenEVP and CMO | SSale | −6.99K | $450.00 | −$3.14M | −21.1%26.1K after | 10b5-1 |
| May 19, 2026 (view filing) | May 15 | 4 days | Bozic CarmenEVP and CMO | SSale | −1.35K | $453.45 | −$614.0K | −5.2%24.7K after | 10b5-1 |
| May 19, 2026 (view filing) | May 15 | 4 days | Bunnage Mark E.EVP, Chief Scientific Officer | SSale | −33 | $453.45 | −$15.0K | −0.5%7.28K after | 10b5-1 |
| Jun 2, 2026 (view filing) | May 29 | 4 days | Bozic CarmenEVP and CMO | SSale | −1.97K | $450.00 | −$888.3K | −8.0%22.8K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Liu JoyEVP and Chief Legal Officer | SSale | −828 | $439.91 | −$364.2K | −4.0%20.0K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 5 | 4 days | Bozic CarmenEVP and CMO | SSale | −1.75K | $450.00 | −$785.3K | −7.7%21.0K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Bozic CarmenEVP and CMO | SSale | −4.06K | $450.00 | −$1.83M | −19.3%17.0K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 18 | 5 days | Bozic CarmenEVP and CMO | SSale | −1.02K | $462.17 | −$471.4K | −6.0%15.9K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Bozic CarmenEVP and CMO | SSale | −596 | $482.50 | −$287.6K | −3.7%15.3K after | 10b5-1 |
| Jul 6, 2026 (view filing)4:13 PM ET | Jul 1 | 5 days | Liu JoyEVP and Chief Legal Officer | SSale | −828 | $502.71 | −$416.2K | −4.1%19.1K after | 10b5-1 |
| Jul 7, 2026 (view filing)4:08 PM ET | Jul 2 | 5 days | McKechnie DuncanEVP, Chief Commercial Officer | SSale | −1.54K | $519.00 | −$799.8K | −12.3%11.0K after | 10b5-1 |
| Jul 7, 2026 (view filing)4:15 PM ET | Jul 2 | 5 days | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | SSale | −1.50K | $524.99 | −$787.5K | −3.2%45.3K after | 10b5-1 |